AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15755847
Drug: Thyroxine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine treatment (n = 99; initial dose 8 microg/kg)
Trial: 2012585
Drug: Creative novation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative novation behaviour therapy (long-term individual therapy, group therapy, bibliotherapy plus short-term individual treatment)
Trial: 6665837
Drug: Tinidazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (40 mg/kg body-weight in one daily dose for five days)
Trial: 6665837
Drug: Tinidazole plus
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole plus diloxanide furoate (tinidazole at 40 mg/kg body-weight in one daily dose for five days and diloxanide furoate at 20 mg/kg body-weight divided into three daily doses for 10 days)
Trial: 30051499
Drug: Dexamethasone 0.75
RxNorm normalized name: dexamethasone 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.75 mg/d
Trial: 30051499
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no extra treatment)
Trial: 25033789
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) 1200 mg/day
Trial: 25033789
Drug: Ginseng 200
RxNorm normalized name: ginseng 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng 200 mg/day
Trial: 22441301
Drug: aranidipine 5-10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aranidipine 5-10 mg/d (n = 118)
Trial: 22441301
Drug: amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5-10 mg/d (n = 118)
Trial: 20122576
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with statins for at least 6 months (group B)
Trial: 20122576
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with statins (group A)
Trial: 12165574
Drug: TRH (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (400 micro g every 8 hours up to 4 doses)
Trial: 10064126
Drug: Hormone analogue
RxNorm normalized name: Melanocyte stimulating hormone analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone analogue (2.5 mg Livial) plus 800 mg calcium
Trial: 10064126
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 800 mg calcium
Trial: 18611062
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 mg (hepatic impairment study)
Trial: 18611062
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 mg (renal impairment study)
Trial: 10591309
Drug: Methylphenidate (Ritalin)
RxNorm normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (Ritalin) hydrochloride at doses of 0.3 mg/kg or 0.6 mg/kg
Trial: 8901800
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (50 mg on alternate days)
Trial: 1831585
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus followed by 2.5 micrograms/kg/min maintenance infusion
Trial: 1831585
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus followed by 5.0 micrograms/kg/min maintenance infusion
Trial: 1831585
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg bolus followed by 10.0 micrograms/kg/min maintenance infusion
Trial: 1831585
Drug: Enoximone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 5.0 micrograms/kg/min maintenance infusion without loading dose
Trial: 6344645
Drug: Orthokeratological (OK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthokeratological (OK) treatment
Trial: 18722511
Drug: Moxifloxacin (preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (preventive antibacterial therapy)
Trial: 16104989
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (n=40)
Trial: 12401624
Drug: 0.15% ropivacaine/fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine/fentanyl 5 micro g/mL
Trial: 12401624
Drug: 0.1% bupivacaine/fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine/fentanyl 5 micro g/mL
Trial: 12401624
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine consumption
Trial: 6107232
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg iv
Trial: 6107232
Drug: Furosemide 80
RxNorm normalized name: furosemide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 80 mg po
Trial: 22079079
Drug: 5%, 10%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%, 10%, 15%, or 20% W(80)5EC combined with 4 or 10 μg strain‐specific Fluzone(®) HA
Trial: 22079079
Drug: 20% W(80)5EC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% W(80)5EC combined with 10 μg strain‐specific HA
Trial: 22079079
Drug: Intranasal PBS
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal PBS
Trial: 22079079
Drug: Intranasal Fluzone(®)
RxNorm normalized name: Fluzone 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Fluzone(®)
Trial: 22079079
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg strain‐specific intramuscular Fluzone(®)
Trial: 20580029
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d with or without medroxyprogesterone acetate 2.5 mg/d
Trial: 17610100
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day CLA plus 2 g/day SFO
Trial: 17610100
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day CLA
Trial: 17610100
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day safflower oil (SFO)
Trial: 8578800
Drug: rgp160 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp160 vaccine in two accelerated schedules (Groups 1 and 2)
Trial: 8578800
Drug: rgp160 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp160 vaccine at 0, 1, 6, and 12 months (Groups 3 and 4)
Trial: 1774408
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of midazolam and alfentanil
Trial: 7037105
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection of oesophageal varices (group 2)
Trial: 29338151
Drug: Oral prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prolonged-release oxycodone/naloxone (OXN) 10 +10 +5 mg every 12 hours
Trial: 29338151
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine patient-controlled analgesia (IVPCA) 2 mg bolus, no basal infusion
Trial: 29338151
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine patient-controlled analgesia (IVPCA)
Trial: 25335250
Drug: Estazolam tablets
RxNorm normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estazolam tablets (1 mg each day for 30 days) (Group C)
Trial: 23986168
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 36 Units of AbobotulinumtoxinA (ABO) into the middle of the lateral orbital rhytides
Trial: 23986168
Drug: Three intradermal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three intradermal injections of 12 Units each of AbobotulinumtoxinA (ABO) along the lateral canthal area
Trial: 18467912
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by placebo for 3 weeks (EAC and placebo)
Trial: 18467912
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by esomeprazole (20 mg) once daily for 3 weeks (EAC and E20)
Trial: 18467912
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg) once daily for 3 weeks after 1 week of esomeprazole (20 mg) bid and placebo antimicrobials (E20 bid and E20)
Trial: 16615116
Drug: Cereal supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal supplement containing folic acid and wheat bran fiber (WBF)
Trial: 1554120
Drug: Propofol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (10 mg = 1 mL)
Trial: 1554120
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL Intralipid)
Trial: 28575484
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion trigger < 10 g/dL, Group 1)
Trial: 28575484
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusion trigger ≤ 7 g/dL, Group 2)
Trial: 26563117
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g L-arginine supplementation
Trial: 26563117
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no L-arginine supplementation)
Trial: 22614148
Drug: 6 g·d⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g·d⁻¹ CLA
Trial: 20456751
Drug: Bemiparin (3500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemiparin (3500 IU subcutaneously once daily for 8 days, followed by bemiparin for 20 additional days)
Trial: 15592872
Drug: IgG(4) antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG(4) antibodies to mink and silver fox urine
Trial: 15592872
Drug: IgG(4) antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG(4) antibodies
Trial: 7793402
Drug: Low-dose amiodarone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amiodarone (mean maintenance dose 268 ± 100 mg/day)
Trial: 1323545
Drug: Phenylpropanolamine (PPA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA), 75 mg sustained release
Trial: 364616
Drug: Ketoprofen (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (75 mg daily orally and 100 mg suppository at night)
Trial: 364616
Drug: Indomethacin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (same dosage as ketoprofen)
Trial: 30910144
Drug: Eryngo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eryngo (5 ml syrup, 3 times a day for 5 days)
Trial: 30910144
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg, 3 times a day for 5 days)
Trial: 30910144
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml syrup, 3 times a day for 5 days)
Trial: 15253848
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (5 weeks, 10 sessions, 10-15 needle insertions per session, needles left in situ for 30-45 minutes)
Trial: 9192551
Drug: E2 protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 protocol (oral care instructions at 1 week before radiotherapy)
Trial: 9192551
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral care instructions)
Trial: 9192551
Drug: E1 protocol
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E1 protocol (oral care instructions at 1 day before radiotherapy)
Trial: 8237937
Drug: alpha-interferon (alfa-2b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-interferon (alfa-2b, 10 million units three times weekly)
Trial: 4035073
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of cyclophosphamide IV 5 mg/kg daily for 6 days immediately after mastectomy
Trial: 4035073
Drug: Delayed adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed adjuvant course of cyclophosphamide IV 5 mg/kg daily for 6 days given 2-4 weeks after mastectomy
Trial: 4035073
Drug: Prolonged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged treatment with IV CMF for 1 year
Trial: 28074489
Drug: Edasalonexent (6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (6000 mg)
Trial: 28074489
Drug: Edasalonexent (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (single dose)
Trial: 9643160
Drug: Lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 4 mg or 6 mg with Hydrochlorothiazide 25 mg added
Trial: 30569637
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)
Trial: 28345429
Drug: Intravenous 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1000 mg uric acid
Trial: 25963345
Drug: Uptitrated Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitrated Metformin
Trial: 23659360
Drug: Both stimulants
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both stimulants
Trial: 23659360
Drug: Shift from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shift from inferior drug to best drug
Trial: 9402845
Drug: CEOP/IMVP-Dexa chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP/IMVP-Dexa chemotherapy and filgrastim (self-injected at 5 micrograms/kg body weight s.c. daily, except on cytotoxic drug days)
Trial: 9402845
Drug: CEOP/IMVP-Dexa chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP/IMVP-Dexa chemotherapy alone
Trial: 7687509
Drug: Relevant foods
RxNorm normalized name: Levant cottonseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relevant foods (foods eliciting positive skin-prick tests and positive oral challenges)
Trial: 7687509
Drug: Non-relevant foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-relevant foods (foods eliciting positive skin tests but negative oral challenges)
Trial: 3323262
Drug: Trimipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (up to 100 mg twice daily)
Trial: 3323262
Drug: Amitriptyline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (up to 100 mg twice daily)
Trial: 30415890
Drug: Oral inosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inosine treatment
Trial: 6660435
Drug: Intranasal verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal verapamil, 1 mg
Trial: 31725644
Drug: Chaihu-Shugan-San (CHSGS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaihu-Shugan-San (CHSGS) capsule
Trial: 31725644
Drug: Tadalafil oral
RxNorm normalized name: tadalafil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil oral pharmacotherapy
Trial: 31725644
Drug: CHSGS capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHSGS capsule
Trial: 28735699
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (Coping Cat)
Trial: 28735699
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and cognitive-behavioral therapy
Trial: 21645330
Drug: Multicomponent pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent pharmacological management protocol for delirium (PMD) including low-dose haloperidol at 0.5-1 mg for 7 days
Trial: 11815505
Drug: Sulfonylurea +
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea + insulin
Trial: 7575256
Drug: Fortified antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified antibiotics (1.5% tobramycin and 10.0% cefazolin solutions)
Trial: 2248109
Drug: Systematic exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic exposure to drug-related cues
Trial: 2248109
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for drug dependence
Trial: 6305670
Drug: ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (150 mg bid)
Trial: 31389755
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of implants (n = 10)
Trial: 31389755
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of implants (n = 10)
Trial: 28090335
Drug: Top-down treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-down treatment
Trial: 27762512
Drug: Noradrenaline (0.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (0.5-3 mg/h)
Trial: 27762512
Drug: Terlipressin (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (0.5-2 mg/6h)
Trial: 21294404
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg simvastatin in the morning
Trial: 21294404
Drug: Evening simvastatin
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening simvastatin administration
Trial: 17506592
Drug: Clodronic acid
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronic acid 800 mg plus elemental calcium 500 mg and 400 IU of vitamin D daily
Trial: 15767608
Drug: Home-based balance-training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based balance-training program using a wobble board for 6 weeks (daily) and 6 months (weekly)
Trial: 12093429
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester (PSE) spread, 2 g daily for 4 weeks
Trial: 12093429
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester (PSE) spread, 3 g daily
Trial: 7477146
Drug: Exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise plus antihypertensive medication
Trial: 2011406
Drug: Molsidomine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (4 mg once acutely, 3 times 4 mg a day for 3 weeks)
Trial: 2011406
Drug: Molsidomine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (after 3 weeks treatment)
Trial: 7009019
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine hydrochloride (20 mgs twice daily)
Trial: 30389226
Drug: Low-dose VWG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose VWG OIT (1445 mg of wheat protein)
Trial: 30389226
Drug: High-dose VWG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VWG OIT (maximum, 2748 mg of wheat protein)
Trial: 30389226
Drug: Low-dose VWG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose VWG OIT
Trial: 25039364
Drug: Alemtuzumab induction
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab induction therapy with reduced doses of tacrolimus, steroids, and mycophenolate mofetil
Trial: 25039364
Drug: Thymoglobulin in
RxNorm normalized name: Thymoglobulin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin in association with standard dose immunosuppression (IS)
Trial: 21824444
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg HCA with a high-carbohydrate meal (2 g carbohydrate/kg body weight, 80 % carbohydrate, 8 % fat, 12 % protein)
Trial: 21824444
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg HCA with a high-carbohydrate meal
Trial: 16973659
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone (ivTA)
Trial: 16973659
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg intravitreal triamcinolone (ivTA)